NewsDr Lalchandani Labs Clarifies Non-Applicability of Large Corporate Status Under SEBI Debt Securities CircularDr Lalchandani Labs Clarifies Non-Applicability of Large Corporate Status Under SEBI Debt Securities Circular
Dr Lalchandani Labs Limited has clarified to BSE that it does not qualify as a 'Large Corporate' under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. The company's long-term borrowings as on March 31, 2026 are less than Rs. 1000 crores, the prescribed threshold for Large Corporate classification. The disclosure was submitted on May 04, 2026, and authorised by Managing Director Arjan Lalchandani.
*this image is generated using AI for illustrative purposes only.
Dr Lalchandani Labs Limited has submitted a formal clarification to BSE Limited, confirming that the company does not qualify as a "Large Corporate" under the criteria prescribed by SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, and its subsequent amendments. The disclosure was made on May 04, 2026, and pertains to the regulatory framework governing fund raising through the issuance of debt securities by large entities.
Basis of Non-Applicability
The company's classification is determined by the level of its long-term borrowings as on March 31, 2026. As per the SEBI circular, entities with long-term borrowings of Rs. 1000 crores or above are categorised as Large Corporates and are subject to mandatory debt market fundraising requirements. Dr Lalchandani Labs has confirmed that its long-term borrowings fall below this prescribed threshold, thereby exempting it from the obligations applicable to Large Corporates.
The key details of the disclosure are summarised below:
| Parameter: | Details |
|---|---|
| Company Name: | Dr Lalchandani Labs Limited |
| CIN: | L85320DL2017PLC321605 |
| Reference Circular: | SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 |
| Long-Term Borrowings (as on March 31, 2026): | Less than Rs. 1000 crores |
| Large Corporate Status: | Not Applicable |
| Disclosure Date: | May 04, 2026 |
| Authorised Signatory: | Arjan Lalchandani, Managing Director (DIN: 07873508) |
Regulatory Context
SEBI introduced the Large Corporate framework to encourage listed entities with significant borrowings to raise a portion of their incremental borrowings through the debt securities market. The circular mandates that companies meeting the threshold criteria comply with specific fundraising norms via the issuance of debt instruments. Companies that do not meet the borrowing threshold are required to submit a declaration confirming their non-applicability, which Dr Lalchandani Labs has duly filed with the exchange.
The disclosure was digitally signed by Managing Director Arjan Lalchandani on May 04, 2026, and submitted to BSE Limited for record and reference purposes.
Historical Stock Returns for Dr Lalchandani Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.94% | +4.58% | -30.21% | -37.61% | +10.84% | -45.66% |
How might Dr Lalchandani Labs' long-term borrowing strategy evolve as the company scales operations, and at what point could it approach the Rs. 1000 crore threshold triggering Large Corporate obligations?
What alternative fundraising mechanisms is Dr Lalchandani Labs likely to pursue for future capital requirements given its current exemption from mandatory debt market issuances?
How does Dr Lalchandani Labs' debt profile and financial leverage compare to peers in the diagnostics and healthcare sector, and what does this imply for its growth trajectory?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
